A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE

Would Be Second US Drug For Eosinophilic Esophagitis

 
• By Mandy Jackson

The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.

Use plan B. Avoid the end and continue on an alternate path.
After hitting a roadblock at the FDA in 2021, Takeda found a new path for TAK-721 • Source: Shutterstock

More from Immunological

More from Therapy Areas